Table 2 Geometric mean levels (GML) of pre- and post-vaccination antibody levels in patients with and without a history of serious infections after vaccination in all patients, and RA and SpA patients respectively
All patients | No serious infections after vaccination | Serious infections after vaccination |
|---|---|---|
N = 470 | N = 27 | |
Antibody levels (mg/L) | Antibody levels (mg/L) | |
GML; 95% CI | GML; 95% CI | |
Serotype 6B | ||
Pre-vaccination | 1.8 (1.6-2.1) | 1.1 (0.6-1.9) |
Post-vaccination | 4.1 (3.5-4.8) | 2.2 (1.3-3.8) |
Serotype 23 F | ||
Pre-vaccination | 0.8 (0.7-0.9) | 0.4 (0.2-0.7) |
Post-vaccination | 2.6 (2.2-3.0) | 1.5 (0.9-2.3) |
RA patients | No serious infections after vaccination | Serious infections after vaccination |
Serotype 6B | ||
Pre-vaccination | 1.7 (1.4-2.1) | 1.0 (0.5-1.8) |
Post-vaccination | 3.1 (2.5-3.9) | 2.0 ( 1.1-3.7) |
Serotype 23 F | ||
Pre-vaccination | 0.7 (0.6-0.8) | 0.3 (0.2-0.7) |
Post-vaccination | 1.8 (1.4-2.1) | 1.4 (0.8-2.4) |
SpA patients | No serious infections after vaccination | Serious infections after vaccination |
Serotype 6B | ||
Pre-vaccination | 1.9 (1.6-2.4) | 2.2 (0.5-9.8) |
Post-vaccination | 5.2 (4.1-6.5) | 3.6 (0.7-17.4) |
Serotype 23 F | ||
Pre-vaccination | 0.8 (0.7-1.0) | 0.7 (0.2-2.3) |
Post-vaccination | 3.6 (3.0-4.5) | 1.9 (0.5-6.9) |